Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

被引：52

作者：

Verstovsek, Srdan ^{[1
]}

Passamonti, Francesco ^{[2
]}

Rambaldi, Alessandro ^{[3
,4
]}

Barosi, Giovanni ^{[5
]}

Rumi, Elisa ^{[6
,7
]}

Gattoni, Elisabetta ^{[8
]}

Pieri, Lisa ^{[9
,10
]}

Zhen, Huiling ^{[11
]}

Granier, Muriel ^{[11
]}

Assad, Albert ^{[11
]}

Cazzola, Mario ^{[6
,7
]}

Kantarjian, Hagop M. ^{[1
]}

Barbui, Tiziano ^{[12
]}

Vannucchi, Alessandro M. ^{[9
,10
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Insubria, Dept Med & Surg, Varese, Italy

[3] Azienda Osped Papa Giovanni XXII, Hematol & Bone Marrow Transplant Unit, Bergamo, Italy

[4] Univ Milan, Dipartimento Oncol & Ematooncol, Milan, Italy

[5] IRCCS Policlin San Matteo Fdn, Ctr Study Myelofibrosis, Fdn Ist Ricovero & Cura Carattere Sci, Pavia, Italy

[6] Univ Pavia, Dept Mol Med, Pavia, Italy

[7] IRCCS Policlin San Matteo Fdn, Dept Hematol Oncol, Pavia, Italy

[8] Osped Santo Spirito, Dept Oncol, Casale Monferrato, Italy

[9] Azienda Osped Univ Careggi, Ctr Res & Innovat Myeloproliferat Neoplasms, Florence, Italy

[10] Univ Florence, Dept Expt & Clin Med, Lab Congiunto Myeloproliferat Neoplasm, Florence, Italy

[11] Incyte Corp, Wilmington, DE USA

[12] Osped Papa Giovanni XXIII, Clin Res Fdn FROM, Bergamo, Italy

来源：

BLOOD | 2017年 / 130卷 / 15期

基金：

美国国家卫生研究院;

关键词：

TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; MYELOPROLIFERATIVE DISORDERS; HIGH-RISK; MUTATION; MYELOFIBROSIS; NEOPLASMS; MANAGEMENT; CRITERIA; THERAPY;

D O I：

10.1182/blood-2017-02-765032

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1768 / 1771

页数：4

共 21 条

[1] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].

Arber, Daniel A. ;

Orazi, Attilio ;

Hasserjian, Robert ;

Thiele, Jurgen ;

Borowitz, Michael J. ;

Le Beau, Michelle M. ;

Bloomfield, Clara D. ;

Cazzola, Mario ;

Vardiman, James W. .

BLOOD, 2016, 127 (20) :2391-2405

[2] Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project [J].

Barosi, Giovanni ;

Mesa, Ruben ;

Finazzi, Guido ;

Harrison, Claire ;

Kiladjian, Jean-Jacques ;

Lengfelder, Eva ;

McMullin, Mary F. ;

Passamonti, Francesco ;

Vannucchi, Alessandro M. ;

Besses, Carlos ;

Gisslinger, Heinz ;

Samuelsson, Jan ;

Verstovsek, Srdan ;

Hoffman, Ronald ;

Pardanani, Animesh ;

Cervantes, Francisco ;

Tefferi, Ayalew ;

Barbui, Tiziano .

BLOOD, 2013, 121 (23) :4778-4781

[3] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].

Baxter, EJ ;

Scott, LM ;

Campbell, PJ ;

East, C ;

Fourouclas, N ;

Swanton, S ;

Vassiliou, GS ;

Bench, AJ ;

Boyd, EM ;

Curtin, N ;

Scott, MA ;

Erber, WN ;

Green, AR .

LANCET, 2005, 365 (9464) :1054-1061

[4] Advances and challenges in the management of essential thrombocythemia [J].

Birgegard, Gunnar .

THERAPEUTIC ADVANCES IN HEMATOLOGY, 2015, 6 (03) :142-156

[5] Comparison of clinicopathologic findings according to JAK2 V617F mutation in patients with essential thrombocythemia [J].

Cho, Young-Uk ;

Chi, Hyun-Sook ;

Lee, Eun-Hye ;

Jang, Seongsoo ;

Park, Chan-Jeoung ;

Seo, Eul-Ju .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (01) :39-44

[6] HYDROXYUREA FOR PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND A HIGH-RISK OF THROMBOSIS [J].

CORTELAZZO, S ;

FINAZZI, G ;

RUGGERI, M ;

VESTRI, O ;

GALLI, M ;

RODEGHIERO, F ;

BARBUI, T .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (17) :1132-1136

[7] Genetic and Epigenetic Complexity in Myeloproliferative Neoplasms [J].

Cross, Nicholas C. P. .

HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM, 2011, :208-214

[8] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis [J].

Harrison, Claire ;

Kiladjian, Jean-Jacques ;

Al-Ali, Haifa Kathrin ;

Gisslinger, Heinz ;

Waltzman, Roger ;

Stalbovskaya, Viktoriya ;

McQuitty, Mari ;

Hunter, Deborah S. ;

Levy, Richard ;

Knoops, Laurent ;

Cervantes, Francisco ;

Vannucchi, Alessandro M. ;

Barbui, Tiziano ;

Barosi, Giovanni .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09) :787-798

[9] Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia [J].

Harrison, CN ;

Campbell, PJ ;

Buck, G ;

Wheatley, K ;

East, CL ;

Bareford, D ;

Wilkins, BS ;

van der Walt, JD ;

Reilly, JT ;

Grigg, AP ;

Revell, P ;

Woodcock, BE ;

Green, AR ;

Pearson, TC ;

Conneally, E ;

Crawley, C ;

Cross, NCP ;

Hall, G ;

Hunt, B ;

Lucas, G ;

Ludlam, C ;

McMullin, MF ;

Oscier, D ;

Radia, D ;

Reilly, JT ;

Robinson, G ;

Culligan, DJ ;

Tighe, J ;

Watson, HG ;

Warren, AJ ;

Awaad, MO ;

Obeid, D ;

Cuthbert, RJG ;

Kyle, A ;

Chan-Lam, D ;

Paul, B ;

Cuthbert, RJG ;

McMullin, MF ;

Morris, TCM ;

Johnson, RJ ;

Fegan, C ;

Milligan, DW ;

Galloway, MJ ;

Williamson, PJ ;

Newton, LJ ;

Williams, AT ;

Abboudi, Z ;

Ryan, K ;

Lush, R ;

Blundell, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (01) :33-45

[10] Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia [J].

Hernandez-Boluda, Juan-Carlos ;

Alvarez-Larran, Alberto ;

Gomez, Montse ;

Angona, Anna ;

Amat, Paula ;

Bellosillo, Beatriz ;

Martinez-Aviles, Luz ;

Navarro, Blanca ;

Teruel, Anabel ;

Martinez-Ruiz, Francisco ;

Besses, Carles .

BRITISH JOURNAL OF HAEMATOLOGY, 2011, 152 (01) :81-88

← 1 2 3 →